• 130. ESMO 2024 - Day 4

  • Sep 17 2024
  • Length: 32 mins
  • Podcast

  • Summary

  • The end of the road approaches, and ESMO 2024 will soon be in the rearview mirror. However, each new day brings new, incredible advances in the treatment of cancer. Today, Josh and Michael dive into biomarker analyses, overall survival updates and new antibody-drug conjugates galore. Listen on for our penultimate summary of ESMO.


    Studies discussed in this episode:

    Biomarker analysis of PEACE-1

    ARANOTE

    STAMPEDE - Addition of Metformin

    Clinical activity of BMS-986365, dual androgen receptor ligand-directed degrader and antagonist in heavily pretreated mCRPC

    Nivo (3mg/kg) + ipi (1mg/kg) in molecularly-selected patients with mCRPC

    Neoadjuvant nivo/rela or nivo/ipi in TNBC with high TILs

    Adjuvant ribo + NSAI in patients with HR+/HER2- EBC: 4 year NATALEE

    Cabozantinib vs placebo for advanced NET after progression on prior therapy (CABINET)

    Osimertinib after definitive CRT: analysis of CNS and distant progression from LAURA

    POTENTIAL


    For more episodes, resources and blog posts, visit www.inquisitiveonc.com

    Please find us on Twitter @InquisitiveOnc!

    If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com


    Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.


    Art courtesy of Taryn Silver

    Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/


    Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.


    Hosted on Acast. See acast.com/privacy for more information.

    Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about 130. ESMO 2024 - Day 4

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.